Abstract:Importance: There is currently no consensus as to which biomarkers best predict longitudinal tau accumulation at different clinical stages of Alzheimer disease (AD).Objective: To describe longitudinal [18F]RO948 tau positron emission tomography (PET) findings across the clinical continuum of AD and determine which biomarker combinations showed the strongest associations with longitudinal tau PET and best optimized clinical trial enrichment.Design, Setting, and Participants: This longitudinal cohort study consecutively enrolled amyloid-β (Aβ)-negative cognitively unimpaired (CU) participants, Aβ-positive CU individuals, Aβ-positive individuals with mild cognitive impairment (MCI), and individuals with AD dementia between September 2017 and November 2020 from the Swedish BioFINDER-2 (discovery cohort) and BioFINDER-1 (validation cohort) studies.Exposures: Baseline plasma and cerebrospinal fluid Aβ42/Aβ40, tau phosphorylated at threonine-217 (p-tau217), p-tau181 and neurofilament light, magnetic resonance imaging, amyloid PET ([18F]flutemetamol), and tau PET ([18F]RO948 in the BioFINDER-2 study; [18F]flortaucipir in the BioFINDER-1 study).Main Outcomes and Measures: Baseline tau PET standardized uptake value ratio (SUVR) and annual percent change in tau PET SUVR across regions of interest derived using a data-driven approach combining clustering and event-based modeling. Regression models were used to examine associations between individual biomarkers and longitudinal tau PET and to identify which combinations best predicted longitudinal tau PET. These combinations were then entered in a power analysis to examine how their use as an enrichment strategy would affect sample size in a simulated clinical trial.Results: Of 343 participants, the mean (SD) age was 72.56 (7.24) years, and 157 (51.1%) were female. The clustering/event-based modeling-based approach identified 5 regions of interest (stages). In Aβ-positive CU individuals, the largest annual increase in tau PET SUVR was seen in stage I (entorhinal cortex, hippocampus, and amygdala; 4.04% [95% CI, 2.67%-5.32%]). In Aβ-positive individuals with MCI and with AD dementia, the greatest increases were seen in stages II (temporal cortical regions; 4.45% [95% CI, 3.41%-5.49%]) and IV (certain frontal regions; 5.22% [95% CI, 3.95%-6.49%]), respectively. In Aβ-negative CU individuals and those with MCI, modest change was seen in stage I (1.38% [95% CI, 0.78%-1.99%] and 1.80% [95% CI, 0.76%-2.84%], respectively). When looking at individual predictors and longitudinal tau PET in the stages that showed most change, plasma p-tau217 (R2 = 0.27, P < .005), tau PET (stage I baseline SUVR; R2 = 0.13, P < .05) and amyloid PET (R2 = 0.10, P < .05) were significantly associated with longitudinal tau PET in stage I in Aβ-positive CU individuals. In Aβ-positive individuals with MCI, plasma p-tau217 (R2 = 0.24, P < .005) and tau PET (stage II baseline SUVR; R2 = 0.44, P < .001) were significantly associated with longitudinal tau PET in stage II. Findings were replicated in BioFINDER-1 using longitudinal [18F]flortaucipir. For the power analysis component, plasma p-tau217 with tau PET resulted in sample size reductions of 43% (95% CI, 34%-46%; P < .005) in Aβ-positive CU individuals and of 68% (95% CI, 61%-73%; P < .001) in Aβ-positive individuals with MCI.Conclusions and Relevance: In trials using tau PET as the outcome, plasma p-tau217 with tau PET may prove optimal for enrichment in preclinical and prodromal AD. However, plasma p-tau217 was most important in preclinical AD, while tau PET was more important in prodromal AD.

Genome-wide scan of Flortaucipir PET levels finds associated with cerebral tau deposition

Genome-wide scan of Flortaucipir PET levels finds JARID2 associated with cerebral tau deposition

Genome-wide Association Study of Brain Tau Deposition As Measured by 18F-Flortaucipir Positron Emission Tomography Imaging.

CYP1B1 - RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET

Tau pathway‐based gene analysis on PET identifies CLU and FYN in a Korean cohort

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer's disease

O3‐04‐02: FLORTAUCIPIR PAIRED HELICAL FILAMENT TAU BURDEN AND CORRELATION WITH COGNITIVE DECLINE IN MCI PATIENTS WITHOUT ANY Aβ

Predicting future rates of tau accumulation on PET

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease

O3‐02‐02: AMYLOID PET, TAU PET, AND MRI MEASUREMENTS IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE, AND NO COPIES OF THE APOE4 ALLELE

Genome-wide Association Study Identifies APOE Locus Influencing Plasma P-Tau181 Levels

Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions

White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

Plasma Glial Fibrillary Acid Protein and Phosphorated Tau 181 Association with Presynaptic Density-Dependent Tau Pathology at 18F-Synvest-1 Brain PET Imaging.

Tau Pathology is Associated with Synaptic Density and Longitudinal Synaptic Loss in Alzheimer’s Disease

Changes of plasma Aβ and t-tau along with 18F-florbetapir PET in a cohort of cognitive decline

INDIVIDUAL-BASED NETWORK ANALYSIS: A NOVEL APPROACH TO INVESTIGATE THE PATHOLOGICAL SPREAD OF PHF TAU USING GRAPH THEORY IN CLINICAL AND PRECLINICAL STAGES OF ALZHEIMER’S DISEASE

Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease

Using Positron Emission Tomography And Florbetapir F 18 To Image Cortical Amyloid In Patients With Mild Cognitive Impairment Or Dementia Due To Alzheimer Disease

Genome-wide Association Study Identifies MAPT Locus Influencing Human Plasma Tau Levels.